glp-1 and cardiovascular benefits Receptor Agonists for the Reduction of Atherosclerotic Risk in Patients With Type 2 Diabetes GLP-1 Agonists: Using Semaglutide, Tirzepatide,

The bottom line Eloralintide is interesting Phase 2 news, but it is not a treatment that is available to patients today

Whether retatrutide triple-agonist approach has already reached that optimal balance or whether it can be improved upon remains an open question

Only 4-8% of people discontinue treatment due to these side effects, most find them manageable

Patients should avoid storing tirzepatide in areas with temperature extremes, such as car glove compartments, near windows with direct sunlight, or in bathrooms where humidity and temperature fluctuate significantly

Athletes using GLP-1s for medical reasons should also ensure their clinician understands their training volume, intensity, and competitive goals

While these medicines are generally safe, many people have reported some side effects 1 , especially during the early stages of treatment 2